ããã°è¨äºã®å¼ç¨ã»è»¢è¼ã¯ãã¹ã¦èªç±ã§ãããã®éããã¼ã¸ã®ãªã³ã¯ã示ãã¦ããã ããã¨å¬ããã§ãã以ä¸ã§ãã¼ã¯ã¼ãè¨äºæ¤ç´¢ãã§ãã¾ãã helsinki.fi ãã¦ã¹ã«ALSãå¼ãèµ·ãããã¨ã«æåãããã¤ã¯ãRNAç ç©¶ æè¿ãmiRNAï¼ãã¤ã¯ãRNAï¼ã«ã¤ãã¦ããµãã¤ã®è¨äºãæ¸ããã¦ããã ãã¾ããã ï¼è¨äºï¼ãå ±éã® miRNA ç¶æ ãã«ããç¾åºãããããããªã2025å¹´é ã®çµæ« In Deep 2023å¹´11æ13æ¥ ï¼è¨äºï¼å¿ççã®åå ã¯ã¹ãã¤ã¯ã¿ã³ãã¯è³ªã§ã¯ãªããã¯ã¯ãã³mRNAã«ããçæããããã¤ã¯ãRNAãã®ãã®ãã§ãããã¨ãç¥ããããã¦ãã¬ã³ã¨å¿ççã¨ALSã®é¥å®´ã®æä»£ãè¿ã⦠In Deep 2023å¹´11æ19æ¥ ããããã¯ãmiRNA ããã¤ã¯ãRNA ã¨è¨ãã¾ããããã®æå¤§ã®å½¹å²ã¯ã ã mRNA ã®ã¿ã³ãã¯è³ªåæã調æ´ããã ã¨ãããã¨ã®ããã§ãã ã§ãã®ã§ããã®èª¿æ´ã®
2023å¹´ããã®ä¸ç ãã£ã¹ããã¢ã¸ãããã 人é¡ã®æªæ¥ æªéã®è¼ªé æ¥æ¬ã®æªæ¥ å¿ççã®åå ã¯ã¹ãã¤ã¯ã¿ã³ãã¯è³ªã§ã¯ãªããã¯ã¯ãã³mRNAã«ããçæããããã¤ã¯ãRNAãã®ãã®ãã§ãããã¨ãç¥ããããã¦ãã¬ã³ã¨å¿ççã¨ALSã®é¥å®´ã®æä»£ãè¿ã⦠mRNA ã¿ã¤ãã®ã¯ã¯ãã³ã¯ãã¹ã¦ç¡çã ã¨ããçµè« å°ãåã«æ¸ããã¦ããã ãã¾ãã以ä¸ã®è¨äºä»¥æ¥ãmiRNA ï¼ãã¤ã¯ãRNAï¼ã¨ãããã®ã«ãããèå³ãæã£ã¦ããã¾ã«åå¼·ãã¦ãã¾ããã ï¼è¨äºï¼ãå ±éã® miRNA ç¶æ ãã«ããç¾åºãããããããªã2025å¹´é ã®çµæ« In Deep 2023å¹´11æ13æ¥ ãã¾ã«åå¼·ã¨ã¯ãã£ã¦ãã1æ¥ 5åã 10åãè«æãæ¤ç´¢ãã¦èªãç¨åº¦ã®ãã¨ã§ããï¼ç§ã¯ 5åã§çè§£ã§ããªãå ´åã諦ããã®ã§ãï¼ãã¯ã¯ãã³é¢é£ã§å°ãããã£ãã®ã¯ã以ä¸ã®ãã¨ã§ãã miRNA 㨠mRNA ã¯ãä½ã ã表è¨ãä¼¼ã¦ãã¦ç´ããããã§ãã®
9æ26æ¥ãå°å å»å¦ã®æ¨©å¨ããéèªãJAMA Pediatricsãã«ãæ¯ä¹³ããmRNAã¯ã¯ãã³ãæ¤åºããããã¨ããè«æãæ²è¼ããã¾ããã ãã®ä»¶ã«ã¤ãã¦ãå°ããæè¡çãªé¢ãããèªã£ã¦ãããã¨æãã¾ãã ãã®è«æã®èè ãã¯ãæ¯ä¹³ããã®RNA精製ã«ãQiagen社ã®ãmiRNeasyãã¨ãããããã使ç¨ãã¾ãããï¼ã«ã¿ãã°çªå·ãããééãããã¾ãããï¼ Detection of Covid-19 vaccine mRNA in BM by qRT-PCR: Covid-19 mRNA vaccines were assayed by two-step RT-PCR. Total RNA was isolated from 0.6 mL of whole milk by miRNeasy mini kit (cat# 217004, Qiagen, Germantown, MD) accord
é£äºå¶éã®ãªãå°¿æ¤æ»ã§ãä»ã®ãããªã¹ã¯ã調ã¹ã¾ããå°¿ã®ãã¤ã¯ãRNAãAIã§è§£æããä¸çåã®æè¡ã§ãé«ç²¾åº¦ã«ãä¸ä¸ãªã¹ã¯ãé«ãã£ãå ´åããä½ç§ã®ç é¢ã§ã©ããªè¿½å æ¤æ»ãåãããããããå ·ä½çã«ãææ¡ãã¾ãã é£äºå¶éã®ãªãå°¿æ¤æ»ã§ãä»ã®ãããªã¹ã¯ã調ã¹ã¾ããå°¿ã®ãã¤ã¯ãRNAãAIã§è§£æããä¸çåã®æè¡ã§ãé«ç²¾åº¦ã«ã ä¸ä¸ãªã¹ã¯ãé«ãã£ãå ´åããä½ç§ã®ç é¢ã§ã©ããªè¿½å æ¤æ»ãåãããããããå ·ä½çã«ãææ¡ãã¾ãã
è¡ä¸ãã¤ã¯ãRNAã«ãã£ã¦13種ã®ãããé«ç²¾åº¦ã«åºå¥ã§ãããã¨ãå®è¨¼ï¼ä¸çæå¤§ã®ããè¡æ¸ ãã¤ã¯ãRNAãã¼ã¿ãã¼ã¹ãå ¬éï¼ 2022å¹´12æ7æ¥ æ ¶æç¾©å¡¾å¤§å¦è¬å¦é¨ æ±äº¬å»ç§å¤§å¦ å½ç«ããç ç©¶ã»ã³ã¿ã¼ å½ç«é·å¯¿å»çç ç©¶ã»ã³ã¿ã¼ æ ¶æç¾©å¡¾å¤§å¦è¬å¦é¨ æ¾å´æ½¤å¤ªéåææãæ±äº¬å»ç§å¤§å¦å»å¦ç·åç ç©¶æ è½è°·ååºææããä¸å¿ã¨ãããå½ç«ããç ç©¶ã»ã³ã¿ã¼ãå½ç«é·å¯¿å»çç ç©¶ã»ã³ã¿ã¼ãæ±ã¬æ ªå¼ä¼ç¤¾ãæ ªå¼ä¼ç¤¾Preferred Networksãªã©ã®å ±åç ç©¶ã°ã«ã¼ãã¯ãããæ£è ã®è¡æ¸ ä¸ã«å«ã¾ãããã¤ã¯ãRNAï¼æ³¨1ï¼ã®ç¶²ç¾ çè§£æãã¼ã¿ããããããã®ç¨®é¡ããé«ã精度ã§åºå¥ã§ãããã¨ãä¸çã«å é§ãã¦å®è¨¼ãã¾ããã æ¬ç ç©¶ã¯ãå½ç«ç ç©¶éçºæ³äººæ¥æ¬å»çç ç©¶éçºæ©æ§ã®æ¬¡ä¸ä»£æ²»çã»è¨ºæå®ç¾ã®ããã®åµè¬åºç¤æè¡éçºäºæ¥ã®æ¯æ´ãåããã使¶²ä¸ãã¤ã¯ãRNAæ¸¬å®æè¡åºç¤éçºããã¸ã§ã¯ããï¼ããã¸ã§ã¯ããªã¼ãã¼ï¼è½è°·ååºææï¼ã¨
ç´°èå·¥å ´ã®ä¸ã§ã®ããã¤ã¯ãRNAãã®å½¹ç®å ¨ä½ã®è¨è¨å³ãDNAãã¨è¨è¨å³ã®é¨ååããRNAãã®é¢ä¿ç§ãã¡ã®ç´°èã¯ãæ¥ã å¤ãã®ã¿ã³ãã¯è³ªã製é ãããã¨ã§ãå½ãæ¯ãã¦ãã¾ãã 髪ãçªãç®èãå¤ããã¿ã³ãã¯è³ªã§æ§æããã¦ããã身ä½ä¸ãæµãã赤è¡çãé ¸ç´ ãéã¹ãã®ããé ¸ç´ éæ¬ç¨ã®ã¿ã³ãã¯è³ªãåå¨ããããã§ãã ç§ãã¡ã®ä½ãæ¯ãã骨ããã³ã©ã¼ã²ã³ã¨ããç®èã«ãåå¨ããã¿ã³ãã¯è³ªã«ã«ã«ã·ã¦ã ãä»çãããã¨ã§å½¢æããã¦ãã¾ãã 人éãåç©ã®ä½ã¯ã常ã«ã¿ã³ãã¯è³ªãä½ãç¶ãã¦ããç´°èã¨è¨ããå°ããªå·¥å ´ããç¡æ°ã«éã¾ã£ã¦ã§ãã¦ããã¨è¨ãã¾ãã ãããå·¥å ´ã®æ©æ¢°è¨åã ããã£ã¦ã製åã¯ã§ãã¾ããã ç´°èå·¥å ´ãã¿ã³ãã¯è³ªã¨ãã製åãä½ãåºãã«ã¯è¨è¨å³ãå¿ è¦ã§ãã ãã®è¨è¨å³ã®å½¹å²ãæããã¦ããã®ãæ ¸ã«åããããDNAã§ãã DNAã«ã¯äººéãç¬ãç«ãªã©ã種ãã¨ã«å¿ è¦ã¨ããå ¨ã¦ã®ã¿ã³ãã¯è³ªã®è¨è¨å³ãå«ã¾ãã¦ãã¾ãã è¨è¨
ä»å¹´ã®ãã¼ãã«ççå¦ã»å»å¦è³ã¯ããã¤ã¯ãRNAã¨ãã®è»¢åå¾éºä¼åå¶å¾¡ã®ä»çµã¿ã®çºè¦ãã®å績ã«ããï¼ç±³ããµãã¥ã¼ã»ãã大å¦ã®ã¢ã³ããã¹ï¼Victor Ambrosï¼ææã¨ãã¼ãã¼ã大å¦ã®ã©ãã«ã³ï¼Gary Ruvkunï¼ææã«æä¸ãããã ããã®éºä¼åã®æ°ã¯ç´2ä¸åããããããï¼ãããã®æ å ±ã ãã§ã¯åç²¾åµãæ£ããæé·ãã¦èµ¤ãåã«ãªããã¨ã¯ã§ããªãããã¤ï¼ä½å ã®ã©ã®å ´æã§ï¼ã©ã®éºä¼åã使ãã°ããããåãããªãããã ãåã2ä¸åã®éºä¼åãæã¤ç´°èãï¼ãããã®ã¯çèã¸ï¼ãããã®ã¯ç¥çµã¸ã¨å ¨ãç°ãªãç´°èã«å§¿ãå¤ããããã«ã¯ï¼éºä¼åã®åããå¶å¾¡ããä»çµã¿ãå¿ è¦ã«ãªãããã®ä»çµã¿ã«é¢ããã®ããã¤ã¯ãRNAã ã ãã¤ã¯ãRNAã¯æ°ååç¨åº¦ã®é·ãã®å¡©åºé åã§ï¼æ®éã®éºä¼åã«æ¯ã¹ãã¨ããã¶ãçãããã¤ã¯ãRNAã¯ã¿ã³ãã¯è³ªã«ç¿»è¨³ããããã¨ã¯ãªããï¼ä»ã®éºä¼åã®mRNAã¨é¨åçã«çµåãã¦ï¼ãã®éºä¼åãåãã¿ã¤ã
ä»å¹´ã®ãã¼ãã«å»å¦ã»ççå¦è³ãçºè¡¨ããããä»å¹´ã®åè³ãã¼ãã¯ããã¤ã¯ãRNAã¨ç¿»è¨³å¶å¾¡ã®çºè¦ãã¨ããäºã ã æ ¸é ¸ã¯ã¯ãã³ã«ã¤ãã¦èª¬æãã¦ä¹ ããããä¸è¬ã®çãããã¡ãã»ã³ã¸ã£ã¼RNAï¼mRNAï¼ã«ã¤ãã¦ã¯ããç¥ã£ã¦ããäºã ã¨æãã䏿¹ã§ããã¤ã¯ãRNAï¼microRNAï¼miRNAï¼ã¨ããã®ã¯ãªãã¿ããªãã®ã§ã¯ãªãã ããããããã¯éºä¼åãã転åãããmRNAã¨ã¯ç°ãªãæ©è½ãæã¤æ¯è¼çå°ããRNAååã§ããã é常ã®ã»ã³ãã©ã«ãã°ãã§ã¯éºä¼åæ å ±ãæã¤DNAããmRNAã転åããããã®é åãåºã«ã¿ã³ãã¯è³ªã翻訳ãããããããé常ã®éºä¼åçºç¾ã®æµãï¼ã»ã³ãã©ã«ãã°ãã®åºæ¬ã§ããã䏿¹ã§miRNAã¯ã¿ã³ãã¯è³ªã¸ã¯ç¿»è¨³ãããã対å¿ããé åãæã¤mRNAã®ç¿»è¨³ãå¶å¾¡ããã¨ããå½¹å²ãæã¤ãæ ¸é ¸ã¯å¯¾å¿ããå¡©åºã«çµåããæ§è³ªãæã£ã¦ãã訳ã ããç¸åé åãæã¤mRNAã«miRNAãçµåãããã¨ã§ãmRNAã®å
2024å¹´10æãããåèªæ²»ä½ã«ããã¦æ°åã³ããã¦ã¤ã«ã¹ã¯ã¯ãã³ã®å®ææ¥ç¨®ãéå§ããã¦ãã¾ãã宿æ¥ç¨®ã§ä½¿ç¨å¯è½ãªã¯ã¯ãã³ã¯ã徿¥ããæ¥ç¨®ããã¦ããmRNAã¯ã¯ãã³ã«å ããçµã¿æãã¿ã³ãã¯è³ªã¯ã¯ãã³ãã¬ããªã³ã³ï¼æ¬¡ä¸ä»£åmRNAï¼ã¯ã¯ãã³ãªã©ã5種é¡ã§ãã ã¬ããªã³ã³ã¯ã¯ãã³ã¯ã徿¥åã®mRNAã¯ã¯ãã³ã¨æ¯ã¹ã¦ãå°ãªãæå¹æåã§é·æéã«ããã£ã¦ææçã®äºé²å¹æãå¾ãããã¨èãããã¦ãã¾ããå®éãåã¯ã¯ãã³ã®æå¹æ§ã¯6ã«ææç¶ãããã¨ã確èªããã¦ãã¾ãããããªä¸ãã¬ããªã³ã³ã¯ã¯ãã³ã®æå¹æ§ã«ã¤ãã¦ã12ã«æã«ããã£ã¦è¿½è·¡èª¿æ»ãè¡ã£ãç ç©¶çµæããä¸ççã«ãæåãªå»å¦èªãLancetãã®å§å¦¹èªã«ã24å¹´10æ7æ¥ä»ã§æ²è¼ããã¾ããã æ¥æ¬ã§è¡ããããã®ç ç©¶ã§ã¯ã18æ³ä»¥ä¸ã®å¥å¸¸è 828人ã対象ã¨ãªãã¾ããã被é¨è ã¯ãã¬ããªã³ã³ã¯ã¯ãã³ãæ¥ç¨®ãã群ã¨ã徿¥åã®mRNAã¯ã¯ãã³ãæ¥ç¨®ãã群ã«ã©ã³ãã
ã¤ã³ãã«ã¨ã³ã¶ã¦ã¤ã«ã¹ã®ææçµè·¯ã¨ãªãé¼»ã«ã¯ã¯ãã³ãç´æ¥å¹ãã¤ããã¹ãã¬ã¼ã¿ã¤ãã®ã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ã®æ¥ç¨®ããåã©ãã対象ã«ä»æããå§ã¾ãã¾ããã æ°ããªã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ããã«ãã¹ããã¯ã¹ãã¬ã¼ãé¼»ã®ä¸ã«å ¥ããç´æ¥å¹ãã¤ããã¿ã¤ãã®ã¯ã¯ãã³ã§ãå»å¹´ãå½ã®æ¿èªãåãã仿ããæ¥ç¨®ã§ããããã«ãªãã¾ããã è¡æ¶²ã®ä¸ã ãã§ãªããã¦ã¤ã«ã¹ã®ä¾µå ¥çµè·¯ã¨ãªãé¼»ãã®ã©ã®ç²èã«ãæä½ãä½ãä½ç¨ãããã徿¥ã®æ³¨å°ããã¿ã¤ãã®ã¯ã¯ãã³ã¨åãç¨åº¦ã®å¹æãããã¨ããã¦ãã¾ãã æ±äº¬ 港åºã®å°å ç§ã®ã¯ãªããã¯ã§ã¯ä»æ7æ¥ããããã®ã¯ã¯ãã³ã®æ¥ç¨®ãéå§ããæ©éãæ¥ç¨®ãåãã親åã訪ãã¦ãã¾ããã ãã®ã¯ã¯ãã³ã«ã¯æ¯æ§ã®å¼±ãã¦ã¤ã«ã¹ãå«ã¾ãã¦ãããããå»å¸«ãå®¶æã«å¦å¨ ä¸ã®äººãããªãããªã©ã確èªããããã§ãç´°ãæ£ç¶ã®ã¹ãã¬ã¼ã«å ¥ã£ãã¯ã¯ãã³ãå·¦å³ã®é¼»ã®ç©´ã«ããããå¹ãã¤ãã¾ããã æ¥ç¨®ãåãã5æ³ã®å¥³ã®åã¯ã注
ã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ã«å¤åãç¹é¼»åã¯ã¯ãã³ãç»å ´ãå¼±æ¯åããã¦ã¤ã«ã¹ãå´å°ããâçã¯ã¯ãã³âããã®å¹æãå¯åå¿ã¨ã¯ï¼ãé³¥åçé³¥åå¸ ããããã®æææµè¡ããã®ãå£ç¯æ§ã¤ã³ãã«ã¨ã³ã¶ãä¾å¹´å¤ãã®äººãæ¥ç¨®ããã¤ã³ãã«ã¨ã³ã¶ã¯ã¯ãã³ã«ä»å¹´ã¯ããå¤åãèµ·ãã¦ãã¾ãã ç§ããå¬ã«ããã¦æµè¡ããå£ç¯æ§ã¤ã³ãã«ã¨ã³ã¶ã10 æããã¯ã¯ãã³æ¥ç¨®ãå§ã¾ã£ã¦ãã¾ãããæ³¨å°ãè¦æã ã¨ããåã©ããå¤ããæ¥ç¨®ã«è¦å´ããå®¶åºãå¤ãã®ã§ã¯ãªãã§ããããã ã¯ã¯ãã³æ¥ç¨®ãããã¨ã®ããåã©ãã®è¦ª ãæ³¨å°ã¯è¦ææèãããã®ã§ãé£ãã¦ããã®ããªããªã大å¤ã§ãã ãããªã¯ã¯ãã³æ¥ç¨®ã«ä»å¹´ã¯ããå¤åãèµ·ãã£ã¦ãã¾ãããä»å¹´ããé¼»ã®ä¸ã«ã¹ãã¬ã¼ãå¹ããããç¹é¼»åã¯ã¯ãã³ã®æ¥ç¨®ã2æ³ãã18æ³ã対象ã«å§ã¾ãã¾ããã 4æ³å ã®æ¯ ãé¼»ã®ç¶¿æ£ï¼ã®æ¤æ»ï¼ãæãåºãã¦ãããã§æãã£ãã®ããªã£ã¦ããã®ããã£ããã©ï¼ç¹é¼»ã§æ¥ç¨®ããå¾ï¼çããªãã£ã
ã¬ããªã³ã³ã¯ã¯ãã³ (èªå·±å¢æ®åmRNAã¯ã¯ãã³) ã¯ä½å ã§èªå·±å¢æ®ããã¯ã¯ãã³ã§ããããã¦RNAè¤è£½ã«ã¯ä¿®å¾©ã®æ©æ§ãç¡ãããã墿®ã®éã«ã¯å¤ç°ãèµ·ããã¾ããããã«å ãæ¸å¿µã¨ãªãã®ã¯ãã¬ããªã³ã³ã¯ã¯ãã³ã¨éçã®ã¦ã¤ã«ã¹ã¨ã®éã§çµæããèµ·ãããæ¬æ¥åå¨ããªãã£ãã¯ãã®æ°è¦ã¦ã¤ã«ã¹ãçã¿åºãäºã§ãã 2024å¹´ï¼æã«ãªã©ã³ãã¨ãªã¼ã¹ãã©ãªã¢ã®å½éçå ±åç ç©¶ã«ãããã¬ããªã³ã³ã¯ã¯ãã³ã¨éçã®ã¦ã¤ã«ã¹ãçµæããèµ·ããå¾ãäºãå ±åããã¾ããã Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo Hick et al. (2024) Molecular Therapy https://www.cell.com/molecular-therapy-fa
次ä¸ä»£ã³ããã¯ã¯ãã³ãã¬ããªã³ã³ããæã£ããâèªå·±å¢æ®âã§ãå¨å²ã«ä¼æãï¼ã宿æ¥ç¨®éå§ã§åºããä¸å®ãäºæ¨ææã解説 ã³ããã¯ã¯ãã³ã®å®ææ¥ç¨®ãå§ã¾ã£ãã ããã¾ã§ã®ãã¡ã¤ã¶ã¼ãã¢ãã«ãã®ã»ãã«ãæ°ãã3種é¡ã®ã¯ã¯ãã³ãå ãããæ¥ç¨®è ã®é¸æè¢ãåºãã£ãããã«æããã ãããä»ããã®ä¸ã®ï¼ã¤ã次ä¸ä»£mRNAã¯ã¯ãã³ï¼ã¬ããªã³ã³ï¼ããããã£ã¦æ¸å¿µã®å£°ãããã£ã¦ããã ã¤ã¡ã¼ã¸ ãã®è¨äºã®ç»åï¼6æï¼ SNSãªã©ãä¸å¿ã«ããå¨å²ã«ã¯ã¯ãã³æåã伿ãããããªã©ã¨ããæ å ±ãæµããã¬ããªã³ã³ã¯ã¯ãã³ãæ¥ç¨®ãã人ã®å ¥åºãå診ãæå¦ããåããèµ·ãã¦ããã®ã ã ããå»é¢ã®HPã«ã¯ããæ¥ç¨®è ã®å¼æ°ããæå®³ãªæ¯ç´ ã大éã«æåºãããåã空æ°ãå ±æãã人ã®å¥åº·ãæãªãå¯è½æ§ããããã¨ã¾ã§æ¸ãã¦ããã ä¸ä½ãã©ããããã¨ãªã®ãï¼ææçå¦ãå°éã®æå大å¦ã»äºæ¨è³äººåèªææã«è©³ãã話ãèããã â ãã¬ããªã³ã³ã¯ã¯ãã³ã
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}